https://www.selleckchem.com/pr....oducts/apx-115-free-
The median OS was 15.4 and 30.9 months in the TDM1 population-based cohort and EMILIA, respectively. Cohort OS was significantly worse than RCT OS (trastuzumab/pertuzumab HR 1.67, 95% CI 1.37-2.03, p less then 0.0001; TDM1 HR 2.80, 95% CI 2.27-3.44, p less then 0.0001). Older patients had worse OS than younger patients for trastuzumab/pertuzumab (HR 1.60, 95% CI 1.19-2.16, p = 0.0018), but not for TDM1 (HR 1.16, 95% CI 0.81-1.66, p = 0.43). CONCLUSION HF incidence during trastuzumab/pertuzumab or TDM1 therapy in this real-
Like
Comment
Share